Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia

Fig. 3

Subgroup analysis of overall survival (OS) and relapse-free survival (RFS) in AML patients according to 2017 ELN risk stratification and different consolidation therapy. a OS for patients in favorable/intermediate risk group based on DNA methylation regulatory gene mutations (DMRGM). b RFS for patients in favorable/intermediate risk group based on DMRGM. c OS for patients in adverse risk group based on DMRGM. d RFS for patients in adverse risk group based on DMRGM. e OS for patients receiving chemotherapy based on DMRGM. f RFS for patients receiving chemotherapy based on DMRGM. g OS for patients receiving HSCT based on DMRGM. h RFS for patients receiving HSCT based on DMRGM

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us